News | Cath Lab | October 06, 2021

Boston Scientific to Acquire Baylis Medical To Expand EP and Structural Heart Portfolios

Acquisition will add new transseptal puncture left heart access platforms, guidewires, sheaths and dilators

The Baylis VersaCross RF transseptal crossing catheter is designed to puncture the septum without a needle to allow access to the left side of the heart for mitral valve and left atrial appendage occlusion procedures. Boston Scientific to Acquire Baylis Medical for $1.75 billion.

The Baylis VersaCross RF transseptal crossing catheter is designed to puncture the septum without a needle to allow access to the left side of the heart for mitral valve and left atrial appendage occlusion procedures. Boston Scientific to Acquire Baylis Medical for $1.75 billion.


October 6, 2021 — Boston Scientific Corp. announced it entered into a definitive agreement to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to closing adjustments. The acquisition will expand the Boston Scientific electrophysiology (EP) and structural heart product portfolios to include the radiofrequency (RF) NRG and VersaCross transseptal puncture platforms, as well as a family of guidewires, sheaths and dilators used to support left heart access. 

These platforms have advanced transseptal puncture and are clinically proven to enhance safety, efficacy and efficiency when crossing the atrial septum to deliver therapies in the left side of the heart, such as atrial fibrillation ablation, left atrial appendage closure (LAAC) and mitral valve interventions.[1,2,3] Baylis is expected to generate net sales approaching $200 million in 2022, having achieved double-digit, year-over-year sales growth during each of the past five years.

"The talented and innovative Baylis Medical Company team, combined with these transseptal platforms, will enhance our efforts to improve procedural efficiencies with physician tools designed to make left atrial access safer and more predictable, with a focus on patient outcomes," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "A leader in many of the fastest growing markets in our industry, we believe that Baylis Medical Company will add meaningful revenue, operating income, and new research and development capabilities across multiple Boston Scientific businesses, while complementing existing offerings within our electrophysiology and structural heart portfolios."

Physicians have traditionally relied on a mechanical needle to pass through the septum and access the left side of the heart, which can present safety concerns and placement challenges based on varying patient anatomy. Rather than relying solely on mechanical force, the Baylis Medical platforms facilitate predictable and safe transseptal access by using RF energy – a method shown to increase efficiency, and improve the safety and efficacy of transseptal puncture during left heart procedures.[1,2,3] 

The new VersaCross platform further streamlines transseptal crossing procedures and therapy delivery by offering the same benefits while eliminating potential wire and sheath exchanges, which may help mitigate risks during procedures.

"As a leading innovator in left heart access solutions, we develop advancements that help physicians deliver critical, high-precision therapies, which raise the standard of care for patients," said Kris Shah, president of Baylis Medical. "We look forward to making these life-changing technologies available to more patients across the globe through the significant commercial reach of Boston Scientific."

Baylis Medical received U.S. Food and Drug Administration (FDA) 510(k) clearance for the NRG platform in 2008 and the technology has since been used in more than 1 million procedures. The company received FDA 510(k) clearance for the VersaCross platform in 2020. These platforms are complemented by the company's family of guidewires, sheaths and dilators, which are designed for use in left-sided diagnostic, ablation, mitral and LAAC procedures.

The transaction is anticipated to close in the first quarter of 2022, subject to customary closing conditions.  
 

References:

1. Jonathan C Hsu, Nitish Badhwar, Edward P Gerstenfeld, et al. Randomized trial of conventional transseptal needle versus radiofrequency energy needle puncture for left atrial access (the TRAVERSE-LA study). Journal of the American Heart Association, September 17, 2013. doi: 10.1161/JAHA.113.000428.

2. Winkle et al. The use of a radiofrequency needle improves the safety and efficacy of transseptal puncture for atrial fibrillation ablation. Heart Rhythm, Volume 8, Issue 9, 2011. DOI 10.1016/j.hrthm.2011.04.032

3. Inohara et al. VersaCross radiofrequency system reduces time to left atrial access versus conventional mechanical needle. J Interv Card Electrophys, 2021; in press (DOI: 10.1007/s10840-020-00931-7)


Related Content

News | Structural Heart

June 7, 2024 — Medtronic today announced new data from the CoreValve Evolut Clinical Program, reinforcing the positive ...

Home June 07, 2024
Home
News | Structural Heart

April 25, 2024 — Atlantic Health System’s Morristown Medical Center treated the first patient in New Jersey using ...

Home April 25, 2024
Home
News | Structural Heart

April 9, 2024 — UC Davis Health cardiology team members are among the first in the country to treat patients with ...

Home April 09, 2024
Home
News | Structural Heart

March 25, 2024 — In a groundbreaking medical advancement, three esteemed cardiologists from CLS Health, Dr. Bahaeddin ...

Home March 25, 2024
Home
News | Structural Heart

March 12, 2024 — Medtronic plc, a global leader in healthcare technology, today announced two late-breaking data ...

Home March 12, 2024
Home
News | Structural Heart

February 20, 2024 — As New Jersey’s leading provider of high-quality cardiac procedures and diagnostic testing and an ...

Home February 20, 2024
Home
News | Structural Heart

February 15, 2024 — Abbott announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee ...

Home February 15, 2024
Home
News | Structural Heart

February 9, 2024 — Physicians in the Smidt Heart Institute at Cedars-Sinai have achieved two significant firsts ...

Home February 09, 2024
Home
News | Structural Heart

January 4, 2024 — Laguna Tech USA, a privately-held medical technology company dedicated to innovations in structural ...

Home January 04, 2024
Home
News | Structural Heart

December 12, 2023 — Think of them as the Energizer Bunnies of the heart, tiny natural batteries that keep this vital ...

Home December 12, 2023
Home
Subscribe Now